171 related articles for article (PubMed ID: 17413701)
1. Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine.
Laurent C; Kouanfack C; Koulla-Shiro S; Njoume M; Nkene YM; Ciaffi L; Brulet C; Peytavin G; Vergne L; Calmy A; Mpoudi-Ngolé E; Delaporte E
AIDS; 2007 Mar; 21(6):768-71. PubMed ID: 17413701
[TBL] [Abstract][Full Text] [Related]
2. [Clinical safety of a generic fixed-dose combination of stavudine/lamivudine/névirapine (Triomune). Study of 297 cases in Togo].
Mouhari-Touré A; Saka B; Kombat K; Tchangaï-Walla K; Pitche P
Bull Soc Pathol Exot; 2008 Dec; 101(5):404-6. PubMed ID: 19192611
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection.
Getahun A; Tansuphasawadikul S; Desakorn V; Dhitavat J; Pitisuttithum P
J Med Assoc Thai; 2006 Sep; 89(9):1472-8. PubMed ID: 17100387
[TBL] [Abstract][Full Text] [Related]
4. HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen.
Marcelin AG; Jarrousse B; Derache A; Ba M; Dakouo ML; Doumbia A; Haidara I; Maïga A; Carcelain G; Peytavin G; Katlama C; Calvez V
AIDS; 2007 Nov; 21(17):2341-3. PubMed ID: 18090283
[TBL] [Abstract][Full Text] [Related]
5. Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon.
Bourgeois A; Laurent C; Mougnutou R; Nkoué N; Lactuock B; Ciaffi L; Liégeois F; Andrieux-Meyer I; Zekeng L; Calmy A; Mpoudi-Ngolé E; Delaporte E
Antivir Ther; 2005; 10(2):335-41. PubMed ID: 15865228
[TBL] [Abstract][Full Text] [Related]
6. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.
Laurent C; Kouanfack C; Koulla-Shiro S; Nkoué N; Bourgeois A; Calmy A; Lactuock B; Nzeusseu V; Mougnutou R; Peytavin G; Liégeois F; Nerrienet E; Tardy M; Peeters M; Andrieux-Meyer I; Zekeng L; Kazatchkine M; Mpoudi-Ngolé E; Delaporte E
Lancet; 2004 Jul 3-9; 364(9428):29-34. PubMed ID: 15234853
[TBL] [Abstract][Full Text] [Related]
8. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
[TBL] [Abstract][Full Text] [Related]
10. Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.
Laurent C; Bourgeois A; Mpoudi-Ngolé E; Ciaffi L; Kouanfack C; Mougnutou R; Nkoué N; Calmy A; Koulla-Shiro S; Delaporte E
AIDS Res Hum Retroviruses; 2008 Mar; 24(3):393-9. PubMed ID: 18327976
[TBL] [Abstract][Full Text] [Related]
11. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.
Calmy A; Pinoges L; Szumilin E; Zachariah R; Ford N; Ferradini L;
AIDS; 2006 May; 20(8):1163-9. PubMed ID: 16691068
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi.
van Oosterhout JJ; Bodasing N; Kumwenda JJ; Nyirenda C; Mallewa J; Cleary PR; de Baar MP; Schuurman R; Burger DM; Zijlstra EE
Trop Med Int Health; 2005 May; 10(5):464-70. PubMed ID: 15860093
[TBL] [Abstract][Full Text] [Related]
13. Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand.
Tsuchiya N; Pathipvanich P; Yasuda T; Mukoyama Y; Rojanawiwat A; Matsubayashi T; Saeng-aroon S; Auwanit W; Matsuyama A; Sawanpanyalert P; Ariyoshi K
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):71-82. PubMed ID: 19323037
[TBL] [Abstract][Full Text] [Related]
14. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
Reliquet V; Ferré V; Hascoet C; Besnier JM; Bellein V; Arvieux C; Molina JM; Breux JP; Zucman D; Rozenbaum W; Allavena C; Raffi F;
Antivir Ther; 1999; 4 Suppl 3():83-4. PubMed ID: 16021876
[TBL] [Abstract][Full Text] [Related]
15. dNN study: stavudine, nelfinavir and nevirapine. Preliminary safety, activity and pharmacokinetic interactions.
Skowron G
Antivir Ther; 1998; 3 Suppl 4():61-2. PubMed ID: 10723513
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.
Tin EE; Bowonwatanuwong C; Desakorn V; Wilairatana P; Krudsood S; Pitisuttithum P
Southeast Asian J Trop Med Public Health; 2005 Mar; 36(2):362-9. PubMed ID: 15916042
[TBL] [Abstract][Full Text] [Related]
17. Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.
van Oosterhout JJ; Kumwenda JJ; Beadsworth M; Mateyu G; Longwe T; Burger DM; Zijlstra EE
Antivir Ther; 2007; 12(4):515-21. PubMed ID: 17668560
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults.
Hosseinipour MC; Corbett AH; Kanyama C; Mshali I; Phakati S; Rezk NL; van der Horst C; Kashuba AD
AIDS; 2007 Jan; 21(1):59-64. PubMed ID: 17148968
[TBL] [Abstract][Full Text] [Related]
19. Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.
Launay O; Gérard L; Morand-Joubert L; Flandre P; Guiramand-Hugon S; Joly V; Peytavin G; Certain A; Lévy C; Rivet S; Jacomet C; Aboulker JP; Yéni P;
Clin Infect Dis; 2002 Nov; 35(9):1096-105. PubMed ID: 12384844
[TBL] [Abstract][Full Text] [Related]
20. Fixed dose combination of lamivudine, stavudine and nevirapine in the treatment of pediatric HIV infection: a preliminary report.
Pensi T
Indian Pediatr; 2007 Jul; 44(7):519-21. PubMed ID: 17684304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
